AT 15, Autumn Fuernisen is dying.
She was diagnosed at age 11 with a rare degenerative brain disorder that has no known cure or way to slow it down: juvenile-onset Huntington’s disease.
“There are a lot of things that she used to be able to do just fine,” said her mom, Londen Tabor, who lives with her daughter in Gillette, Wyoming, United States.
Autumn’s speech has become slurred and her cognitive skills, slower.
She needs help with many tasks, such as writing, showering and dressing, and while she can walk, her balance is off.
Autumn has been turned down for clinical trials because she is too young.
“It is so frustrating to me,” Tabor said. “I would sell my soul to try to get any type (of treatment) to help my daughter.”
For patients like Autumn with serious or immediately life-threatening conditions who do not qualify for clinical trials and have exhausted all treatment options, there may be another option: seeking approval from the Food and Drug Administration (FDA) for expanded access, or compassionate use, of experimental therapies.
Definitive numbers are hard to find, but studies from researchers, actions by drugmakers and insights from experts suggest that getting expanded access to unproven therapies for rare diseases is more difficult than for more common illnesses, such as cancer.
Even with experimental treatments on the rise, patients with rare diseases frequently face an unwillingness by drug companies to provide them the drugs before clinical studies are completed.
Complicated process
Developing drugs for these diseases is an especially fragile process because the patient populations are small and often diverse, having different genetics, symptoms and other characteristics, which makes studying the drugs’ effects difficult.
Drugmakers believe offering a drug before studies are finished could impair its development and jeopardise FDA approval.
Companies working on therapies for rare diseases, especially smaller ones, could feel those repercussions acutely, said Lisa Kearns, a researcher in the ethics division of New York University’s medical school and member of the division’s working group on compassionate use and preapproval access.
“There’s not as much investment in rare diseases, so an (adverse) event could frighten the already limited number of potential investors,” she said.
Drugs that were not made available for compassionate use last year until studies were completed include Evrysdi, for spinal muscular atrophy; Enspryng, for an autoimmune disease of the optic nerve and spinal cord called neuromyelitis optica spectrum disorder; and Viltepso, for certain patients with Duchenne muscular dystrophy.
A spokesperson for Roche, which makes Evrysdi and Enspryng and is working on a treatment for Huntington’s disease, said the decision was not tied to the type of disease, but to company policy: Roche does not set up expanded access programmes for any drugs until results are available from a phase 3 clinical trial.
Another company’s experimental drug for myasthenia gravis, an autoimmune disease that leads to skeletal muscle weakness, similarly was not available through an expanded access programme until research was completed last year, and no programmes have started for a therapy being studied in a phase 3 clinical trial for Huntington’s disease and for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, often referred to as Lou Gehrig’s disease.
One slight, but notable, deviation: Drugmaker Biogen agreed this year to allow certain ALS patients to receive an experimental drug on July 15, after the testing was completed but before the results were known.
Finding matches
Dr Merit Cudkowicz, a neurologist at Massachusetts General Hospital in Boston, has helped patients get therapies through expanded access.
Since September 2018, she and her colleagues launched 10 programmes that seek to match people with ALS therapies being developed by drug companies, but only about 120 patients have received therapies this way.
More than 16,000 people in the US were estimated in 2015 to have ALS and most do not qualify for clinical trials because of the progression of their disease or very strict eligibility requirements.
These examples contrast with some drugs for more common problems.
Gleevec, for leukaemia, was offered to thousands of patients through expanded access programmes before the manufacturer completed the clinical studies that led to FDA approval.
Videx, for HIV/AIDS, and Iressa, for the most common type of lung cancer, were similarly offered to large numbers of patients even as clinical trials were ongoing.
Last year, Novartis gave more than 7,000 patients worldwide early access to cancer drugs.
Doctors also report that getting experimental drugs for cancer patients is relatively simple.
More than 200 physicians around the country were surveyed, and among those who applied for access, nearly 90% said they had secured drugs still being investigated for patients who were not responding to approved therapies.
California researchers found similar trends in a review of 23 social media campaigns launched by patients between 2005 and 2015 seeking a variety of experimental treatments.
While seven of the 19 patients with cancer received early access to requested drugs, no access was allowed for three patients with rare diseases, although one of those patients was allowed to enrol in a clinical trial.
Difficult decisions
Companies base their decisions on whether to provide a therapy through expanded access on a number of factors, said Jess Rabourn, the chief executive officer of WideTrial, which helps pharmaceutical companies run compassionate use programmes.
In general, there should be evidence that patients can tolerate the treatment and an expectation that any benefit outweighs the risk, he said.
“This idea that you have to wait until the research is done is baloney,” he said. “We’re talking about patients who are going to die if they’re told to wait.”
But drugmakers often view it differently, even though evidence suggests that granting early access very rarely disrupts drug approval.
Kearns explained that companies often wait until phase 3, or after, because they can be “relatively” confident of a drug’s safety and effectiveness.
“They don’t want to harm patients, of course, but they also do not want to threaten the drug’s eventual regulatory approval with an adverse event in (a) very sick patient population,” she said.
Melissa Hogan, who consults on clinical trials for rare diseases and is an FDA patient representative, attributes the lack of access to the high cost of therapies and the tightknit nature of the rare disease community, where patients and their families often set up social media groups and exchange ideas and treatment plans.
Companies “know that if one patient gains access, other patients will know” and ask for access, said Hogan, who has a son with mucopolysaccharidosis type II.
That could overwhelm small drugmakers with little manufacturing capacity.
These concerns cause “many companies (to) just throw up their hands and take a hard line of no (expanded access) until they reach approval stage,” said Hogan.
A different route
The 2018 Right to Try law offers another option for some patients.
Unlike expanded access, the law applies only to requests for medicines – not medical devices – and does not require approval from the FDA or an institutional review board, a committee that reviews and monitors people participating in research for their protection.
The legislation, however, doesn’t oblige companies to grant a request.
For Cali Orsulak, expanded access may be her husband’s only option.
He was diagnosed with ALS in 2019 at age 43.
“We did our best with the skill level we had to search clinical trials all over Canada and the US, and then Covid-19 hit and it became increasingly difficult,” said Orsulak, explaining that they live in Canada but seek medical care in the US.
“Now that my husband has progressed, it’s even harder to get into clinical trials.” – Christina Bennet/Kaiser Health News/Tribune News Service
Kaiser Health News (KHN) is a national newsroom that produces in-depth journalism about health issues.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
